bs-0982R

## [ Primary Antibody ]

## phospho-NFKB p65 (Ser536) Rabbit pAb



www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

DATASHEET -

Host: Rabbit Isotype: IgG

Clonality: Polyclonal

**GenelD:** 5970 **SWISS:** Q04206

Target: NFKB p65 (Ser536)

Immunogen: KLH conjugated Synthesised phosphopeptide derived from human

NFKBp65 around the phosphorylation site of Ser536: FS(p-S)IA.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50%

Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated

freeze/thaw cycles.

Background: NF-kappa-B is a ubiquitous transcription factor involved in several biological processes. It is held in the cytoplasm in an inactive state by specific inhibitors. Upon degradation of the inhibitor, NF-kappa-B moves to the nucleus and activates transcription of specific genes. NF-kappa-B is composed of NFKB1 or NFKB2 bound to either REL, RELA, or RELB. The most abundant form of NF-kappa-B is NFKB1 complexed with the product of this gene, RELA. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011].

Applications: WB (1:500-2000)

**IHC-P** (1:100-300) **IHC-F** (1:100-300) **IF** (1:100-300)


Reactivity: Mouse (predicted: Human,

Rat, Monkey)

Predicted 61 kDa MW.:

Subcellular Cytoplasm ,Nucleus

## VALIDATION IMAGES -



NIH/3T3 (M) cells were treated with or without Calvculin A (100nM) for 30 min, 25 ug total protein per lane of cell lysates (see on figure) probed with phospho-NFKB p65 polyclonal antibody, unconjugated (bs-0982R) at 1:2000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

## — SELECTED CITATIONS —

- [IF=17.521] Yi Yan. et al. Nanomedicines Reprogram Synovial Macrophages by Scavenging Nitric Oxide and Silencing CA9 in Progressive Osteoarthritis, Advanced Science, 2023 Feb::2207490 WB: Mouse, 36748885
- [IF=15.304] Sitong Liu. et al. MRI-visible mesoporous polydopamine nanoparticles with enhanced antioxidant capacity for osteoarthritis therapy. BIOMATERIALS. 2023 Apr;295:122030 WB; Mouse. 36758340
- [IF=12.4] Manikandan Santhanam. et al. Interaction of SMAC with a survivin-derived peptide alters essential cancer hallmarks: Tumor growth, inflammation, and immunosuppression. MOL THER. 2024 Apr 05 WB; Mouse. 38582961
- [IF=11.7] Ran Cheng, et al.Intratumoral antigen-presenting cell activation by a nanovesicle for the concurrent tertiary lymphoid structure de novo neogenesis.science advances.2025 Feb 21;11(8):eadr1299.; MOUSE. 39970209

pec;:e10475 WB ;Mouse. 10.1002/btm2.10475						